Neuroplast

Executive Summary

Neuroplast is a clinical-stage biotechnology company based in the Netherlands, pioneering autologous stem cell therapies for neurodegenerative conditions. Its proprietary Neuro-Cells® platform is designed to counteract neurodegeneration resulting from trauma, disease, and aging. Founded in 2017, the company has secured European Orphan Drug Designations for spinal cord injury and frontotemporal dementia, underscoring the therapeutic potential of its approach. While still in early clinical development, Neuroplast's focus on addressing high unmet medical needs and its differentiated technology position it as a promising player in the cell and gene therapy space. The company is privately held and continues to advance its pipeline toward key value-driving milestones.

Upcoming Catalysts (preview)

• H2 2026Initiation or update of Phase 2 clinical trial for spinal cord injury40% success
• H1 2027Regulatory progress for frontotemporal dementia program (e.g., Orphan Drug Designation extension or clinical trial application)50% success
• 2026Publication of preclinical or early clinical data supporting Neuro-Cells® platform60% success